Peer Review History

Original SubmissionJune 29, 2025
Decision Letter - Yu-Chi Liu, Editor

PONE-D-25-27081 Evaluation effect of umbilical cord blood serum drops in the treatment of severe dry eye in patients with Sjogren's syndrome and mustard gas chemical veterans: Protocol for a randomized clinical trial PLOS ONE

Dear Dr. rostami,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 16 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Yu-Chi Liu, MD, PhD

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

3. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 1 in your text; if accepted, production will need this reference to link the reader to the Table.

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: As the statistical reviewer I will focus on methods and reporting. Overall the approaches are appropriate and clearly reported.

Major

1) I would recommend regression based modeling to estimate ORs and SEs for the outcomes of interest, so they can be used in power calculations (as opposed to p-values)

2) Please follow the CONSORT statement.

3) linked to point 1, please clarify how findings will inform future power calculations and for which outcome.

4) clarify how you will deal with missing data in the trial. multiple imputation?

5) I don't understand why participants are not blinded - a clear justification is needed since this is a major limitation for the primary (self-reported) outcome.

Minor

1) justify the selected sample, is it just down to feasibility? resources?

2) Can you clarify where and how data will be shared?

Reviewer #2: This study protocol addresses a clinically relevant problem, and the use of human umbilical cord blood serum drops represents an innovative approach. This therapy may offer an effective treatment option for severe dry eye in patients with Sjögren’s syndrome and chemical ocular injury by using biologically active components with regenerative potential. However, several methodological and reporting issues need clarification and refinement to strengthen the protocol.

Study design: The trial includes two distinct populations, Sjögren’s patients and mustard gas–exposed veterans. The rationale for including both groups is not clearly explained. Based on the methods, it appears that the analyses for the two populations will be conducted independently. A clearer justification for this hybrid design is needed, and the background section should better support the inclusion of mustard gas–exposed patients.

Title: The current title is somewhat confusing. The study combines a between group RCT (Group A and B) with a within-subject paired-eye design (group C). However, the primary comparison is not directly between the Sjogren's syndrome and mustard gas chemical injury. Consider revising the title to more accurately reflect the study design and objectives.

Sample size: No sample size calculation is provided. The protocol would be strengthened by using preliminary or pilot data to estimate the number of participants needed per group, along with the expected effect size, power, and significance level. Without this information, it is difficult to assess feasibility and statistical robustness.

Follow-up duration: The proposed 60-day follow-up may be too short to capture sustained treatment effects, particularly in chronic conditions such as Sjögren’s syndrome and chemical injury–related dry eye. A longer follow-up period should be considered if feasible.

Outcome measures: The current outcome set is limited to conventional clinical and patient-reported measures. Including additional objective endpoints, such as in vivo confocal microscopy (IVCM), could provide valuable insight into corneal nerve changes and ocular surface regeneration, thereby strengthening the study’s conclusions.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Chang Liu

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Dear Dr. Yu-Chi Liu,

We sincerely appreciate the time and effort you and the reviewer have dedicated to evaluating our manuscript, "Evaluation effect of umbilical cord blood serum drops in the treatment of severe dry eye in patients with Sjogren's syndrome and mustard gas chemical veterans: Protocol for a randomized clinical trial" (Manuscript ID: PONE-D-25-27081). We are grateful for the constructive feedback, which has helped us improve the quality of our work.

We have carefully addressed all the comments and suggestions provided by the reviewer. Below, we provide a point-by-point response to each remark, detailing the revisions made in the revised manuscript. All changes have been highlighted in the revised version for easy reference in yellow.

Reviewer #1:

We sincerely thank you for your insightful and detailed comments.

Comment 1: "I would recommend regression based modeling to estimate ORs and SEs for the outcomes of interest, so they can be used in power calculations (as opposed to p-values)”

Response 1: We have revised the "Statistical Analysis" section to focus on estimation rather than hypothesis testing. The plan now uses regression modeling to estimate effect sizes (Odds Ratios and mean differences) and their confidence intervals, which will be used to inform the power calculations for a future definitive trial (lines 288-308).

Comment 2: "Please follow the CONSORT statement.”

Response 2: Since this manuscript presents the protocol of an ongoing RCT, the appropriate reporting guideline is the SPIRIT 2013 statement rather than CONSORT, which is intended for completed RCTs with results. The SPIRIT checklist is available as an attachment in the submission portal.”

Comment 3: "Please clarify how findings will inform future power calculations and for which outcome.”

Response 3: As this study is a pilot trial, the main goal is to obtain preliminary estimates of effect size and variability for planning a future definitive RCT. We will specifically use the Ocular Surface Disease Index (OSDI) score, our primary outcome, to calculate the mean difference and standard deviation between groups. These estimates will then be used to perform formal power and sample size calculations for the main trial, targeting a clinically meaningful improvement in OSDI score. We made the necessary amendments (lines 309-313).

Comment 4: "clarify how you will deal with missing data in the trial. multiple imputation?”

Response 4: Given the small sample size and exploratory nature of this pilot trial, we will first aim to minimize missing data through close follow-up and reminders. In the event of missing outcome data, we will conduct the primary analysis using an intention-to-treat (ITT) approach, with multiple imputation by chained equations (MICE) applied if more than 10% of data are missing for the primary outcome (OSDI score). We made the necessary amendments (lines 314-319).

Comment 5: "I don't understand why participants are not blinded - a clear justification is needed since this is a major limitation for the primary (self-reported) outcome.”

Response 5: We fully acknowledge that the absence of participant blinding may introduce potential bias, particularly given that the primary outcome (OSDI) is self-reported. However, blinding participants was not feasible in this pilot study because the appearance, viscosity, and storage requirements of umbilical cord blood serum differ markedly from conventional artificial tears, making it practically impossible to mask the intervention.

To minimize potential bias, we ensured that outcome assessors (ophthalmologist and optometrist) were blinded to treatment allocation, and objective measures (TBUT, fluorescein staining, SM tube test) are also included as secondary outcomes. We will clearly discuss this as a limitation and interpret subjective outcomes with appropriate caution. (lines 337-344).

Comment 6: "justify the selected sample, is it just down to feasibility? resources?”

Response 6: The selected sample size (10 participants per group) was primarily determined based on feasibility and available resources, as this is an exploratory pilot study intended to assess study procedures, recruitment capability, and preliminary effect sizes. Our decision also aligns with methodological recommendations suggesting that pilot RCTs typically include 10–15 participants per group to provide reliable estimates of variability for planning a larger definitive trial.

Therefore, the sample size reflects both practical feasibility and methodological precedent for pilot investigations. We made a clarification about this ( lines 284-286)

Comment 7: "Can you clarify where and how data will be shared?”

Response 7: Thank you for raising this issue. We added a data availibility declaration (lines 362-365).

Reviewer #2

Thank you for taking the time to share your valuable feedback with us.

Comment 1: "The trial includes two distinct populations, Sjögren’s patients and mustard gas–exposed veterans. The rationale for including both groups is not clearly explained. Based on the methods, it appears that the analyses for the two populations will be conducted independently. A clearer justification for this hybrid design is needed, and the background section should better support the inclusion of mustard gas–exposed patients.”

Response 1: By including these two populations, we aim to evaluate whether HUCB serum can promote ocular surface healing in different etiological contexts (autoimmune and chemically induced) thus broadening the potential clinical applicability of this intervention.

Analyses for the two groups will indeed be conducted independently, as they represent two separate sub-studies within the same pilot framework. This hybrid design allows efficient use of study infrastructure while generating preliminary data for both populations to inform future, population-specific definitive trials.

We have revised the Background and Study design sections to clarify this rationale and to better emphasize the relevance of mustard gas–exposed veterans to the study’s regenerative focus (lines 126-130 and 148-152).

Comment 2: "The current title is somewhat confusing. The study combines a between group RCT (Group A and B) with a within-subject paired-eye design (group C). However, the primary comparison is not directly between the Sjogren's syndrome and mustard gas chemical injury. Consider revising the title to more accurately reflect the study design and objectives”

Response 2: We agree that the original title may give the impression of a direct comparison between Sjögren’s syndrome and mustard gas–induced dry eye, which is not the case.

To better reflect the study design and objectives, we have revised the title as follows:

Evaluation of umbilical cord blood serum eye drops for severe dry eye in two distinct populations—Sjögren’s syndrome and mustard gas–induced ocular injury: Protocol for a pilot randomized clinical trial.

In case if you have a title in your mind that better reflects the hybrid nature of our study, we are more than willing to hear it (lines 1-3).

Comment 3: "No sample size calculation is provided. The protocol would be strengthened by using preliminary or pilot data to estimate the number of participants needed per group, along with the expected effect size, power, and significance level. Without this information, it is difficult to assess feasibility and statistical robustness.”

Response 3: As this is a pilot study, its primary aim is to assess feasibility, safety, and variability of the outcomes to inform a future adequately powered randomized controlled trial. For this reason, a formal sample size calculation based on power and significance testing was not performed. Nonetheless, the selected sample size of 10 participants per group was determined according to methodological guidance suggesting that 10–15 participants per arm are adequate in pilot RCTs to estimate variance and feasibility parameters for future trials.

Comment 4: "The proposed 60-day follow-up may be too short to capture sustained treatment effects, particularly in chronic conditions such as Sjögren’s syndrome and chemical injury–related dry eye. A longer follow-up period should be considered if feasible”

Response 4: We fully agree that a longer follow-up period would be ideal to assess the durability of treatment effects, particularly in chronic conditions such as Sjögren’s syndrome and chemical injury–related dry eye.

However, due to resource limitations, logistical constraints, and the exploratory nature of this pilot trial, extending follow-up beyond 60 days is not currently feasible. The 60-day period was selected to allow a practical yet clinically meaningful observation window to evaluate short-term safety, feasibility, and preliminary efficacy signals of the intervention.

We plan to use the findings from this pilot to support a future definitive RCT with a longer follow-up duration to assess sustained outcomes. This clarification has been added to the Discussion section (lines 344-349).

Comment 5: "The current outcome set is limited to conventional clinical and patient-reported measures. Including additional objective endpoints, such as in vivo confocal microscopy (IVCM), could provide valuable insight into corneal nerve changes and ocular surface regeneration, thereby strengthening the study’s conclusions”

Response 5: Although advanced imaging tools such as IVCM could provide valuable results, the present pilot study was designed primarily to assess feasibility and short-term clinical outcomes using established subjective and objective measures. Due to equipment and resource limitations, IVCM was not included in this phase.

Sincerely,

Masoud Rostami

Attachments
Attachment
Submitted filename: Response 2025-10-10.docx
Decision Letter - Yu-Chi Liu, Editor

Evaluation of umbilical cord blood serum eye drops for severe dry eye in two distinct populations—Sjögren’s syndrome and mustard gas–induced ocular injury: Protocol for a pilot randomized clinical trial

PONE-D-25-27081R1

Dear Dr. rostami,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yu-Chi Liu, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I am satisfied with the authors' responses and the resulting changes to the paper. Nothing else to add.

Reviewer #2: Thank you for the authors’ revisions. The authors have addressed and explained my previous comments, and the manuscript has been improved. As a study protocol, I have no further major concerns and recommend the manuscript for publication after minor editorial review.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Yu-Chi Liu, Editor

PONE-D-25-27081R1

PLOS ONE

Dear Dr. Rostami,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

A/Prof Yu-Chi Liu

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .